Guangzhou Innogen Pharmaceutical Group Co Ltd Sustainability Reports
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of therapies for diabetes and other metabolic diseases. Its core product, efsubaglutide alfa, is a humanized long-acting GLP-1 receptor agonist approved in China for treating type 2 diabetes.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
FIGI: BBG01WK1C4Z3
1 reports from 2025 to 2025
